Quantifying the Contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial

Journal of Urology

Volumn 187, Issue 5, 2012, Pages 1732-1738

  Roehrborn, Claus G ^a   Wilson, Timothy H ^b   Black, Libby K ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

biomarkers; pharmacological; prostate; prostatic hyperplasia; questionnaires; urination disorders

Indexed keywords

DUTASTERIDE; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORGAN SIZE; PATIENT PERCEPTION OF STUDY MEDICATION; PATIENT SATISFACTION; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUANTITATIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT OUTCOME; URINE FLOW RATE;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AZASTEROIDS; DOUBLE-BLIND METHOD; HUMANS; MALE; PATIENT SATISFACTION; PROSTATIC HYPERPLASIA; QUESTIONNAIRES; SULFONAMIDES;

EID: 84859526268     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.12.083     Document Type: Article

References (12)

1. AUA guideline on management of benign prostatic hyperplasia: (2003) Chapter 1: diagnosis and treatment recommendations J Urol 170 2003 530
2. S. Madersbacher, G. Alivizatos, J. Nordling EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines) Eur Urol 46 2004 547
3. V. Watson, M. Ryan, C.T. Brown Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia J Urol 172 2004 2321
4. S.J. Hong, W. Rayford, L. Valiquette The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management BJU Int 95 2005 15
5. L. Black, A. Grove, B. Morril The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary track symptoms Health Qual Life Outcomes 7 2009 55
6. P. Siami, C.G. Roehrborn, J. Barkin Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design Contemp Clin Trials 28 2007 770
7. C.G. Roehrborn, P. Siami, J. Barkin The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study Eur Urol 57 2010 123
8. C. Acquadro, K. Conway, C. Girourdet Linguistic Validation Manual for Patient Reported Outcomes (PRO) Instruments 2004 MAPI Research Trust Lyon
9. Food and Drug Administration Guidance for Industry: Patient Reported Outcome Measures: Use in Medicinal Product Development to Support Labeling Claims (Draft Guidance) Department of Health and Human Services, Food and Drug Administration 2006 http://www.fda.gov/CDER/GUIDANCE/5460dft.pdf Accessed November 7, 2011.
10. M.J. Barry, W.O. Williford, Y. Chang Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 154 1995 1770
11. J. Barkin, C.G. Roehrborn, P. Siami Effect of dutasteride, tamsulosin and the combination on patient reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial BJU Int 103 2009 919
12. J.D. McConnell, C.G. Roehrborn, O.M. Bautista The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387